1. Home
  2. HLIO vs PVLA Comparison

HLIO vs PVLA Comparison

Compare HLIO & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HLIO

Helios Technologies Inc.

SELL

Current Price

$68.51

Market Cap

2.3B

Sector

Industrials

ML Signal

SELL

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

SELL

Current Price

$131.32

Market Cap

1.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
HLIO
PVLA
Founded
1970
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.9B
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
HLIO
PVLA
Price
$68.51
$131.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
15
Target Price
$94.67
★ $228.93
AVG Volume (30 Days)
★ 350.8K
191.6K
Earning Date
11-02-2026
11-10-2026
Dividend Yield
★ 0.70%
N/A
EPS Growth
23.93
★ 52.62
EPS
★ 1.25
N/A
Revenue
★ $200,727,000.00
$42,810,000.00
Revenue This Year
$6.91
N/A
Revenue Next Year
$5.86
N/A
P/E Ratio
$55.10
★ N/A
Revenue Growth
N/A
★ 65.28
52 Week Low
$49.00
$68.96
52 Week High
$95.05
$161.38

Technical Indicators

Market Signals
Indicator
HLIO
PVLA
Relative Strength Index (RSI) 44.45 38.49
Support Level $66.25 $109.68
Resistance Level $69.41 $135.23
Average True Range (ATR) 1.78 7.02
MACD 0.25 -0.51
Stochastic Oscillator 27.77 24.37

Price Performance

Historical Comparison
HLIO
PVLA

About HLIO Helios Technologies Inc.

Helios Technologies Inc is an industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic components and systems used to transmit power and control force, speed, and motion. There are two categories based on Hydraulic system architecture: MCT and FCT. The Electronics segment provides complete, fully-tailored display and control solutions for engines, engine-driven equipment, specialty vehicles, therapy baths, and traditional and swim spas. The company generates the majority of its revenue from the Hydraulics segment. Geographically, the company generates key revenue from the Americas region.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Share on Social Networks: